2389-49-3

Basic information

• Product Name: methyl N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysinate
• Synonyms: methyl N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysinate;N2-Cbz-N6-Boc-L-Lys-OMe;N6-[(1,1-Dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysine methyl ester;Z-N6-Boc-L-Lys-OMe;2-(benzyloxycarbonylamino)-6-(tert-butoxycarbonylamino)hexanoic acid methyl ester;methyl 6-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(phenylmethoxycarbonylamino)hexanoate;(S)-Methyl13,13-diMethyl-3,11-dioxo-1-phenyl-2,12-dioxa-4,10-diazatetradecane-5-carboxylate
• CAS NO: 2389-49-3
• Molecular Formula: C₂₀H₃₀N₂O₆
• Molecular Weight: 394.462
• EINECS: 219-222-6
• Mol File: 2389-49-3.mol
• Article Data: 13

Chemical Properties

• Melting Point: 62.5-63.5 °C
• Boiling Point: 544.7°Cat760mmHg
• Flash Point: 283.2°C
• Appearance: /
• Density: 1.13g/cm³
• Vapor Pressure: 6.34E-12mmHg at 25°C
• Refractive Index: 1.507
• Storage Temp.: 2-8°C
• PKA: 10.95±0.46(Predicted)
• CAS DataBase Reference: methyl N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysinate(2389-49-3)
• EPA Substance Registry System: methyl N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysinate(2389-49-3)

Safety Data

• Hazardous Substances Data: 2389-49-3(Hazardous Substances Data)

Usage

Uses

Z-Lys(Boc)-OMe is used in the preparation and surfactant-free synthesis of stimuli-responsive cationic nanoparticles.

InChI:InChI=1/C20H30N2O6/c1-20(2,3)28-18(24)21-13-9-8-12-16(17(23)26-4)22-19(25)27-14-15-10-6-5-7-11-15/h5-7,10-11,16H,8-9,12-14H2,1-4H3,(H,21,24)(H,22,25)

Upstream product

• 14511-39-8 2(S)-2-amino-6-(benzylideneamino)hexanoic acid 
• 2389-60-8 Z-Lys(Boc)-OH 
• 74-88-4 methyl iodide 
• 657-27-2 L-Lysine hydrochloride 
• 501-53-1 benzyl chloroformate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2418-95-3 (S)-2-amino-6-(tert-butoxycarbonylamino)hexanoic acid 
• 706810-26-6 N^ε-(3-methyl-2-butenyl)oxycarbonyl-L-lysine methyl ester 
• 648910-27-4 N^α-benzyloxycarbonyl-N^ε-(3-methyl-2-butenyl)oxycarbonyl-L-lysine methyl ester 
• 13515-95-2 lysine methyl ester dihydrochloride 
• 5591-93-5 (S)-methyl 6-amino-2-(benzyloxycarbonylamino)hexanoate 
• 67-56-1 methanol 
• 186581-53-3 diazomethane 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 

Downstream Products

• 3017-32-1 (S)-methyl 2-amino-6-(tert-butoxycarbonylamino)hexanoate 
• 5591-93-5 (S)-methyl 6-amino-2-(benzyloxycarbonylamino)hexanoate 
• 1401318-34-0 C₂₇H₂₉N₅O₃ 
• 1401318-33-9 C₂₆H₂₉N₅O₄S 
• 1401318-32-8 (S)-benzyl tert-butyl (6-azidohexane-1,5-diyl)dicarbamate 
• 122477-82-1 tert-butyl-N-[(5S)-5-(benzyloxycarbonylamino)-6-hydroxyhexyl]carbamate 
• 1263383-05-6 6-((2S,4S)-1-(tert-butoxycarbonyl)-4-(tert-butoxycarbonylamino)pyrrolidine-2-carbonylamino)-2-(3,4,5-tris(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)benzamido)hexyl methacrylate 
• 1263383-04-5 6-((2S,4S)-1-(tert-butoxycarbonyl)-4-(tert-butoxycarbonylamino)pyrrolidine-2-carbonylamino)-2-(3,4,5-tris(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)benzamido)hexyl alcohol 

Relevant articles and documents

Serine- and threonine-derived diamine equivalents for site-specific incorporation of platinum centers in peptides, and the anticancer potential of these conjugates

A modular strategy that allows introduction of one or more reactive platinum units at chosen locations along a peptide sequence is presented. This makes use of diazides generated from serine and threonine as diamine equivalents which can be conjugated to the peptide under standard coupling conditions. Reduction of these diazides using Pd/C and H2 followed by platination affords the final products in good yields. Following this, we prepared a new class of peptide-platinum conjugates and carried out preliminary cytotoxicity evaluation and DNA interaction studies. Inclusion of lysine residues in the sequence was found to improve DNA interaction and anticancer activities compared to analogous conjugates with hydrophobic side chains.

Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists

A conjugated compound of Formula I: Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II:

Cobalt (III) complexes as novel matrix metalloproteinase-9 inhibitors

-